Alkermes plc

ALKS

IE00B56GVS15

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:39:01 2024-04-19 am EDT			5-day change	1st Jan Change
23.74 ^USD	-0.06%		-3.11%	-14.71%

Apr. 09	Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday	MT
Apr. 09	Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study	MT

Alkermes plc(NasdaqGS:ALKS) dropped from Russell Midcap Value Index

June 25, 2021 at 12:00 am EDT

Latest news about Alkermes plc

Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday	Apr. 09	MT
Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study	Apr. 09	MT
Alkermes plc Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia	Apr. 09	CI
Alkermes Insider Sold Shares Worth $292,740, According to a Recent SEC Filing	Mar. 19	MT
Baird Initiates Alkermes With Outperform Rating, Price Target is $37	Mar. 19	MT
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors	Mar. 07	CI
European Equities Traded in the US as American Depositary Receipts Advance Wednesday	Mar. 06	MT
Alkermes Shares Down After Downgrade From UBS	Feb. 20	MT
UBS Downgrades Alkermes to Sell From Neutral, Price Target is $25	Feb. 20	MT
Piper Sandler Raises Price Target on Alkermes to $39 From $32.54, Maintains Overweight Rating	Feb. 16	MT
Sector Update: Health Care Stocks Higher Late Afternoon	Feb. 15	MT
Sector Update: Health Care Stocks Higher Thursday Afternoon	Feb. 15	MT
Alkermes Shares Rise After Q4 Results, Guidance	Feb. 15	MT
Transcript : Alkermes plc, Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Alkermes Q4 Non-GAAP Earnings, Revenue Increase; 2024 Outlook Issued -- Shares Gain Pre-Bell	Feb. 15	MT
Earnings Flash (ALKS) ALKERMES Posts Q4 Revenue $377.5M, vs. Street Est of $362.4M	Feb. 15	MT
Alkermes plc announces an Equity Buyback for $400 million worth of its shares.	Feb. 15	CI
Alkermes plc Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Alkermes plc Provides Earnings Guidance for the Year 2024	Feb. 15	CI
Alkermes plc authorizes a Buyback Plan.	Feb. 14	CI
Alkermes plc Announces Executive Changes	Feb. 05	CI
Transcript : Alkermes plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 11:15 AM	Jan. 10
Alkermes plc Announces Topline Results from Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI	Jan. 03	CI
Alkermes plc(NasdaqGS:ALKS) added to S&P 1000	Dec. 18	CI
Alkermes plc(NasdaqGS:ALKS) added to S&P 600 Health Care	Dec. 18	CI

Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Alkermes plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

23.76 USD

Average target price

35.25 USD

Spread / Average Target

+48.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALKERMES PLC	-14.71%	4.02B
IQVIA HOLDINGS INC.	-1.62%	41.35B
LONZA GROUP AG	+41.70%	40.38B
MODERNA, INC.	+3.03%	39.05B
CELLTRION, INC.	-12.11%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.94%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-23.58%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.32%	11.68B
MEDPACE HOLDINGS, INC.	+21.22%	11.6B
UNITED THERAPEUTICS CORPORATION	+7.36%	11.15B

Other Biotechnology & Medical Research

Alkermes plc

Equities

ALKS

IE00B56GVS15

Biotechnology & Medical Research

Alkermes plc(NasdaqGS:ALKS) dropped from Russell Midcap Value Index

Latest news about Alkermes plc

Chart Alkermes plc

Company Profile

Income Statement Evolution

Ratings for Alkermes plc

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research